New hope for hard-to-treat leukemia: experimental combo enters early testing
Disease control
Not yet recruiting
This early-phase study tests a new drug called lonitoclax combined with azacitidine in 66 adults with acute myeloid leukemia (AML) that has returned or not improved after prior therapy. The main goal is to find the safest dose and see if the combination can shrink or control the …
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC